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Abstract
Background: Pertussis toxin (PTX), an exotoxin of Bordetella pertussis, enhances the development of experimental
autoimmune diseases such as experimental autoimmune uveitis (EAU) and experimental autoimmune encephalomyelitis
(EAE) in rodent models. The mechanisms of the promotion of experimental autoimmune diseases by PTX may be based
upon PTX-induced disruption of the blood eye/brain barriers facilitating the infiltration of inflammatory cells, the
modulation of inflammatory cell migration and the enhancement of the activation of inflammatory cells. We hypothesized
that the facilitation of experimental autoimmunity by PTX suggests that its influence on the in vivo immune response to
auto-antigen may differ from its influence on non-self antigens.
Methodology/Principal Findings: We have evaluated the effect of PTX on the simultaneous generation of delayed type
hypersensitivity (DTH) responses and autoimmune responses to uveitogenic interphotoreceptor retinoid binding protein
peptide (IRBP161–180), encephalitogenic myelin oligodendrocyte glycoprotein peptide (MOG35–55) or ovalbumin (OVA). PTX
injection of mice immunized to IRBP peptide161–180 led to (i) the development of EAU as shown by histopathology of the
retina, (ii) pro-inflammatory cytokine production by splenocytes in response to IRBP peptide 161–180, and (iii) symptomatic
EAE in mice immunized with encephalitogenic MOG peptide35–55. However, mice that received PTX had a reduced DTH
response to IRBP161–180 peptide or MOG peptide35–55 when challenged distal to the site affected by autoreactive T cells.
Moreover, footpad challenge with MOG35–55 peptide reduced EAE in mice immunized with MOG peptide. In contrast, the
use of PTX when immunizing with OVA protein or an OVA immunogenic peptide did not affect the DTH response to OVA.
Conclusions/Significance: The results suggest that that the reduced DTH response in mice receiving PTX may be specific for
autoantigens and autoantigen-reactive T cells are diverted away from ectopic sites that received the autoantigen and
towards the tissue site of the autoantigen.
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Introduction
Autoimmune uveitis, a disease that targets neural retina, is
characterized by massive uveal inflammation, vasculitis, and the
destruction of photoreceptor cells. Experimental autoimmune
uveitis (EAU) is induced in mice by active immunization with
evolutionarily conserved retinal proteins such as interphotoreceptor
retinoid binding protein (IRBP), Complete Freunds’ Adjuvant
(CFA) and pertussis toxin [1–4]. Pertussis toxin (PTX), derived from
Bordatella perttussis is usually required to induce experimental
autoimmune disease. In addition to amplifying the activation of
immunocompetent cells and proinflammatory cytokine production
[5,6]; PTX may play a role in opening the blood/brain barrier, and
influences the migratory patterns of inflammatory cells [7–11]. In
aggregate, PTX induces changes in vascular permeability, thus
facilitating the breakdown of blood–tissue barriers and thereby
facilitates the infiltration of inflammatory cells into the target organ.
Despite the use of PTX for over two decades to enhance the
induction of experimental autoimmune disease, the mechanism of
its action is still not yet understood. Although some of the
enhancing effects of PTX on the induction of experimental
autoimmunity are thought to be due to changes in vascular
permeability when administered at the time of immunization,
PTX also promotes the production of Th1 cytokines and low doses
of PTX promote a delayed-type hypersensitivity response [10,12].
The effects of PTX on antigen-presenting cells may underlie this
phenomenon [13,14]. Pertussis toxin also modulates the immune
response to neural antigens injected with Incomplete Freund’s
Adjuvant: inducing Th1 cells and experimental autoimmune
encephalomyelitis (EAE) in the presence of high frequencies of
Th2 cells [14]. However, high doses of the toxin can result in
reduced disease or DTH [5,10]. The mechanism of this strict dose
dependency of the effect of PTX is unknown.
Because PTX enhances proinflammatory cytokine production
and Th1-based autoimmune diseases, we investigated the role of
PTX in the induction of delayed-type hypersensitivity (DTH) to
self-peptides in conjunction with the induction of autoimmune
disease models. We observed that although PTX is critical for
development of EAU in mice immunized with CFA, PTX and the
uveitogenic peptide IRBP161–180, PTX reduced or retarded DTH
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reducing cellular infiltration at the site of challenge even though
PTX enhanced the production of proinflammatory cytokines. This
inhibitory effect of PTX on DTH is limited to self antigens
suggesting that the apparent inhibition of DTH to the autoanti-
gens may be due to differential a migration of antigen specific
lymphocytes and retention of effector T cells at a site expressing
the self antigen.
Materials and Methods
Animals
Female C57BLB10.RIII-H2rH2-T18b (C57BLB10.RIII) and
C57BL6 mice 6–8 weeks old were purchased from Jackson
Laboratories (Bar Harbor ME and Charles River Laboratories
(Wilmington, MA, USA) respectively. All animals were maintained
by the Center for Laboratory Animal Care at the University of
Connecticut Health Center. The use of animals adhered to the
Association for Research in Vision and Ophthalmology (ARVO)
resolution on the use of animals in ophthalmic and vision research.
All work with animals has been reviewed and approved by the
University of Connecticut Health Center Animal Care Committee
(ACC 2004-380).
Antigens and reagents
Human IRBP peptide161–180 (SGIPYIISYLHPGNTILHVD)
that constitutes a major pathogenic epitope for C57BL10.RIII
mice[4,12] wasprepared byAnaspec Laboratories,SanDiego,CA.
Myelin oligodendrocyte glycoprotein peptide35–55 (MOG35–55)w a s
prepared by the Yale University W.M. Keck Facility. Ovalbumin
(OVA) peptide; (TEWTSSNVMEERKIKV amino acids 265–280)
for CD4 T cells purchased from Invitrogen Life Sciences (Carlsbad,
CA) was the generous gift of Drs. A. Vella and A. Menoret,
Department of Immunology, University of Connecticut Health
Center. Ovalbumin protein was purchased from Sigma (St. Louis,
MO). Pertussis toxin (PTX) was purchased from List Biological
Laboratories, Campbell,CA. Complete Freund’s adjuvant
(CFA),Incomplete Freund’s Adjuvant (IFA) and Mycobacterium
tuberculosis strain H37RA were purchased from Difco (Detroit, MI).
Induction and scoring of EAU [15]
Mice were immunized on the dorsal surface of their back
intradermally with a 0.2 ml of the emulsion of 50–100 mg
IRBP161–180 peptide in CFA (1:1, v/v), containing 2.5 mg/ml of
M. tuberculosis H37RA. Mice were injected with PTX, 1 mgi n
phosphate-buffered saline (PBS, pH 7.2) in a total volume of
0.1 ml i.p. 24 h after immunization with IRBP and CFA. Freshly
enucleated eyes were collected for histopathology on specific days
after immunization, and were fixed in 4% paraformaldehyde
(PFA) solution. The incidence and severity of EAU was scored on
an arbitrary scale of 0–4 on hematoxylin and eosin-stained
sections, according to a semi quantitative system described [15].
Two independent observers did the scoring in blinded manner and
results compared. The clinical scale measured was as follows: 0 =
normal, 1 = mild distortion of layers of retina, 2 = mild to
moderate distortion of layers of retina and minimal inflammatory
cell infiltrate, 3 = moderate distortion of layers of retina and
massive inflammatory cell infiltrate and 4 = severe distortion of
retinal layers with total disruption of retinal architecture and
massive cellular infiltrate.
Induction and scoring of Experimental Allergic
Encephalomyelitis
For the induction of active EAE, C57BL/6 mice were injected
intradermally (ID) with 200 mg of emulsion containing 200 mg
MOG35–55 in Incomplete Freund’s Adjuvant (IFA) supplemented
with 500 mgo fM. tuberculosis. Mice were injected i.p with 200 ng
PTX in 100 ml of PBS shortly after and 48 h after the first
immunization. Following immunization, animals were kept under
observation to score the disease. The study was done in a blinded
fashion. The clinical scale measured was as follows: 0 = normal,
1 = limp tail, 2 = paraparesis with a clumsy gait, 3 = hind limb
paralysis, 4 = quadriplegia, 5 = death.
Induction of Delayed-Type Hypersensitivity
To induce a maximum DTH response mice were immunized
with a subcutaneous (sc) injection of 50 ml CFA containing 100 mg
emulsified IRBP peptide161–180, or 200mg MOG peptide35–55,
50 mg OVA265-280 peptide or 200 mg OVA protein into a flank.
The control group did not receive any immunization or in some
cases CFA without IRBP, MOG peptide or OVA. Seven days
after immunization the mice were anesthetized with ketamine
(75 mg/kg) and xylazine (15 mg/kg) and footpad thickness of both
hind footpads measured with a digital micrometer (Mitatoyo,
Tokyo, Japan). One footpad was challenged with an intradermal
(ID) injection of 50 mg IRBP161-180 peptide, MOG35-55 peptide,
OVA or OVA265-280 peptide in PBS and the other footpad was
challenged with PBS only. Approximately 24, 48 and sometimes
72 h later, the mice were anesthetized with ketamine/xylazine and
footpad thickness re-measured. Swelling was computed as the
difference in thickness (in mm) of the challenged footpad at 24 h
minus the difference in thickness (in mm) of the vehicle-challenged
Figure 1. Induction of EAU with IRBP peptide. C57BL10.RIII mice received sc IRBP peptide161–180,+ CFA. Twenty-four hr later the mice received
PTX i.p. Fourteen or 21 days P.I. the mice were euthanized, eyes enucleated, sectioned and stained with H&E. Figure is representative of sections from
5 individual mice.
doi:10.1371/journal.pone.0011983.g001
DTH in Autoimmunity
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collected and fixed in 4% paraformaldehyde (PFA). Histopathol-
ogy sections were taken and stained with hematoxylin and eosin
(H&E). Sections were analyzed for leukocyte infiltration and
inflammatory cell accumulation.
In Vitro Stimulation of T cells with IRBP peptide
Splenocytes were obtained from immunized mice on day 7-post
immunization. Splenocytes were cultured at 37uC in flat bottom
12 well plates at a concentration of 1610
7 cells/well and
stimulated with 100 ng IRBP peptide or medium only in a
volume of 0.5 ml. Supernatants were harvested 24 h post in-vitro
culture and stored at 220uC. until assayed for cytokines.
Cytokine assays
Supernatants that were collected after 24 h from in-vitro
cultures were assayed for presence of cytokines (IL-1ß, TNF-a,
IFN-c and IL-10) by ELISA using kits from R & D Laboratories
(Minneapolis,MN) as described by the manufacturer.
Statistics
Footpad swelling and cytokine assays were compared between
groups and a paired t-test was used to do statistical analysis. In all
comparisons, P,0.05 was used to determine statistical signifi-
cance.
Results
Induction of EAU by IRBP peptide161–180
C57BL10.RIII mice were immunized with IRBP peptide161–180,
CFA and PTX and euthanized on days 14 or 21 PI. The eyes were
enucleated; sections obtained and stained with H&E. Sections were
analyzed for integrity, architecture of the retinal layer and
mononuclear cell infiltrate. The histopathology of the eyes of mice
receiving CFA + PTX only, CFA or PTX only, or CFA + IRBP
peptidebutno PTX were nodifferent from mice receivingPBSonly
or no injection. Mice that received 50–100 mg IRBP peptide, CFA
and1 mg PTXattainedalossofarchitectureoftheretinallayersand
extensive mononuclear cell infiltration 14 days P.I. (Fig 1). The
histopathology of the retinal layer was similar on day 14 P.I. in mice
immunized with 50 or 100 mg IRBP peptide. Extensive mononu-
clear cell infiltration and a marked disorder of the retinal outer
nuclear layer (EAU score 3+) was observed by day 14 or 21 in mice
receiving 50 or 100 mg IRBP peptide and 0.5–1 mg PTX. EAU was
diminished significantly by day 21 P.I. in mice immunized with 25
or 50 mg IRBP peptide but was maintained in mice receiving
100 mg IRBPpeptide(Fig.2).Althoughdamagetotheouternuclear
layer of the retina was extensive by day 21 P.I., the infiltrate of
mononuclear cells was diminished.
PTX enhances Th1 cytokine production but diminishes
the DTH response to IRBP peptide161–180
Cytokine production. Fourteen days after C57BL10.RIII
mice were immunized with IRBP peptide161–180, spleens were
recovered and spleen cells cultured +/2 the IRBP peptide.
Splenocytes recovered from mice immunized with CFA, IRBP and
PTX produced measurable amounts of TNF-a and IFN-c when
cultured in vitro without IRBP peptide (Figure 3A,B). However,
mice receiving PTX produced 5-35-fold more TNF-a or IFN-c.
More cytokines were produced when the splenocytes were
cultured with lipopolysaccharide (LPS) and IRBP peptide (data
not shown).
Figure 2. Dose/response and kinetics of the development of
EAU by immunization with IRBP peptide. Mice were immunized
with IRBP peptide161–180, CFA and PTX. Mice were euthanized 7,14 or 21
days P.I., eyes enucleated and sectioned and stained with H&E. EAU is
scored as described in Materials and Methods and the data represent
the average score +/2S.E.M. of 5–6 mice/group.
doi:10.1371/journal.pone.0011983.g002
Figure 3. PTX potentiates the production of Th1 cytokines by
splenocytes. C57BL10.RIII mice were immunized with IRBP peptide161–
180, CFA +/2 PTX. Splenocytes were obtained from immunized mice on
day 7 or 14 days P.I. Splenocytes were cultured at 37uC. in flat bottom
12 well plates at a concentration of 1610
7 cells/well and stimulated
with 100 mg IRBP peptide or medium only in a volume of 0.5 ml.
Supernatants from 3 cultures were harvested 24 h post in-vitro culture
and stored at 220uC. Supernatants were assayed by ELISA for TNF-a or
IFN-c ˜.
doi:10.1371/journal.pone.0011983.g003
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generation of EAU and the production of inflammatory cytokines,
we reasoned that PTX would also enhance a DTH response to
IRBP peptide. To test this hypothesis, mice were immunized with
IRBP peptide, CFA and varying doses of PTX. Seven days P.I. a
footpad of the immunized mice was challenged with an intradermal
injection of IRBP peptide. Footpad thickness was measured pre, 24,
and 48 hr post challenge. Although mice immunized with 12.5,
25 mg IRBP peptide and CFA produced footpad swelling
approximately 50% greater than naı ¨ve mice when challenged
with IRBP peptide (data not shown) maximum swelling was
achieved in mice immunized with 100 mg IRBP peptide and CFA
(Figure 4). However mice receiving 1 and 5 mg PTX post
immunization with IRBP peptide and CFA had markedly
reduced swelling after challenge. In many instances this reduction
in swelling in mice receiving PTX was noted at 24 hours post
challenge but sometimes was less profound at 48 hr post challenge.
Seventy-two hr post challenge the increment in swelling in mice
Figure 4. DTH to IRBP peptide161–180 is diminished in mice receiving PTX. C57BL10.RIII mice were immunized with IRBP peptide, CFA +/2
PTX. Seven days P.I. a footpad was challenged with an intradermal injection of IRBP peptide and swelling measured 24 and 48 hr after challenge. The
data represents the footpad swelling +/2 S.E.M. of 6–8 mice/group in two experiments.
doi:10.1371/journal.pone.0011983.g004
Figure 5. Pertussis toxin reduces the cellular infiltrate in the DTH response to IRBP peptide161–180. C57BL10.RIII mice were immunized
with IRBP peptide 161–180, CFA +/2 PTX. Seven days P.I. a footpad was challenged with intradermal IRBP peptide161–180. Twenty four hr after challenge
footpads were harvested, sectioned and stained with H&E. Section is 10X and represents footpad of one of three mice.
doi:10.1371/journal.pone.0011983.g005
DTH in Autoimmunity
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no effect on DTH swelling in mice injected with less than 250 ng
PTX (data not shown). Thus, there is a dichotomy in
proinflammatory cytokine production by splenocytes and DTH
responses in the periphery. H & E sections of the challenged
footpads (Fig 5) revealed a reduced mononuclear cell infiltratein the
challenged footpad of immunized mice that received PTX.
PTX fails to diminish the DTH response to OVA but
reduces the DTH response to MOG35–55 peptide
We investigated the effect of PTX on immunization for a local
DTH response to OVA protein, OVA265–280 peptide or the
encephalitogenic MOG peptide35–55 by immunizing C57BL/6
mice with MOG peptide, OVA protein, OVA265–280 peptide,
CFA +/2 PTX. Seven days after immunization, a footpad of the
immunized mice was challenged with intradermal OVA265–280
peptide or MOG35–55 peptide. Footpad swelling to a challenge
with OVA protein or OVA peptide was not affected by the
administration of PTX during immunization (Fig 6A,B). In
contrast, 7 days P.I. in mice immunized with encephalitogenic
MOG35–55 peptide CFA and PTX, the local DTH response to
MOG35–55 peptide was reduced significantly as compared to mice
immunized with MOG35–55 peptide and CFA only. However,
mice receiving PTX with MOG35–55 peptide PTX and CFA had
robust EAE 14 days P.I. (Fig 7). However, EAE was reduced at
day 14 in MOG35–55 peptide-immunized mice whose footpad
received intradermal MOG peptide on day 7 P.I. EAE was not
affected in MOG peptide immunized whose footpad was
challenged with IRBP peptide.
Discussion
The induction of EAU in C57BL10.RIII mice by immunization
with IRBP peptide161–180, CFA and PTX is well documented [1–
5,12,15]. Consistent with those reports we observed that EAU was
not induced unless the mice received PTX post- immunization
with IRBP peptide and CFA. EAU was characterized by a strong
infiltration of mononuclear cells to the retina and extensive
damage to the retinal outer nuclear layer. By day 21, damage to
the outer nuclear layer was equal to or greater than that observed
14 days P.I. but more than 21 days P.I., the number of infiltrated
mononuclear cells was reduced markedly or not detected.
Additionally, 21+ days P.I. there appeared to be some resolution
of damage to the outer nuclear layer of the retina (data not shown).
PTX enhanced the production of the Th1 cytokines IFN-c and
TNF-a7 days P.I. consistent with the effect of PTX on the
enhancement of the induction of cell-mediated immunity
[5,6,10,12]. In fact, Th17 cells, essential to autoimmunity and
DTH [16–18] are promoted by PTX [19]. Accordingly, we
reasoned that PTX would also enhance a DTH response in the
C57BL10.RIII mice immunized with CFA and IRBP. To our
surprise, we found that the DTH-induced swelling of footpads of
Figure 6. PTX reduces DTH to MOG35–55 peptide but not to OVA. (A) C57BL/6 mice were immunized with MOG 35–55 peptide or OVA, CFA +/
2 PTX. Seven days P.I. footpads of the mice were challenged with intradermal MOG peptide35–55 or OVA respectively. Swelling was measured 24 and
48 hr later. Data represents the mean swelling (mm) +/2S.E.M. of five mice/group. The experiment was done twice. (B) C57BL10.RIII mice were
immunized with OVA265–280 peptide, CFA +/2 pertussis toxin. Seven days P.I, footpads were challenged with 50 mg OVA35–55 peptide and swelling
measured 24 hr post-challenge.Data represents the mean +/2S.E.M. of 4 mice. NS: not significant.
doi:10.1371/journal.pone.0011983.g006
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absent or reduced markedly in mice receiving PTX. This swelling
correlated with a reduced number of monocytic cells that
infiltrated the site challenged with IRBP peptide161–180. Our
results with IRBP peptide differ from those of Silver et al [12] who
demonstrated an enhancement of DTH to IRBP protein in
C57BL10.RIII mice receiving PTX. However, Silver et al
measured DTH to IRBP -induced DTH on day 21 P.I. rather
than day 7 P.I. using significantly lower amounts of PTX.
Although we observed lower DTH on day 21 P.I., 24 hr after
challenge, there was a modest reduction in swelling in the footpads
of mice immunized with IRBP peptide and CFA only and some
increase in swelling in mice receiving PTX (Fig 4). However, the
increase in swelling in the group receiving PTX was transient and
not apparent 72 hr after challenge. Although we observed
extensive damage to the outer nuclear layer by day 21 P.I.,
monocytic infiltration to the retina was reduced markedly. Silver et
al did not get robust DTH without PTX although in our hands
mice immunized with MOG161–180 peptide and CFA (without
PTX) did develop robust DTH. Additionally, the enhancement of
DTH by PTX is due to the B subunit while the A subunit may
induce the inhibition of an autoimmune response, or, at the doses
of PTX we used, the inhibition of DTH [5].
Although the DTH response of C57BL/6 mice to OVA or OVA
peptidewasnot influencedbyPTX,theDTHresponseofC57BL/6
mice to encephalitogenic MOG35–55 peptide was diminished in
mice immunized with MOG35–55 peptide, CFA and PTX even
though these mice exhibited robust EAE. However, EAE was
significantly reduced in these mice after their footpad was
challenged with MOG peptide but not with IRBP peptide 161–180.
Thus, mice immunized with IRBP or MOG (self) peptide, CFA
and a PTX dose that facilitates the induction of autoimmunity had
a strong immune response to these autoantigens yet exhibited a
diminished or absent DTH reaction when challenged with the
autopeptides. In contrast, immunized mice that did not receive
PTX (that did not develop autoimmunity) have a strong DTH
response to the self-peptides. Moreover, the DTH response to
OVA was not affected by PTX. In fact, PTX can amplify the
DTH response to bacterial antigens [20]. Although PTX is
thought to modulate lymphocyte migration [12,21], the adminis-
tration of PTX before sensitized mice are challenged with the
cognate antigen does not inhibit the DTH reaction [21].
Therefore, it is unlikely that PTX administered 6–10 days before
the challenge affected the DTH response by activated T cells that
includes the recruitment of monocytic cells. In aggregate, because
the suppression of DTH by PTX is localized to self antigens, it is
tempting to speculate that the lack of a local DTH response in
mice with a localized, ongoing autoimmune response is due to a
‘‘diversion’’ of sensitized T cells to the site(s) containing the
autoantigen, eg the retina (IRBP) or neurons (MOG). In that
regard, the apparent reduction in EAE in MOG-immunized mice
that received a challenge to the footpad with MOG peptide could
be due to a diversion of antigen-reactive T cells to the challenge
site. These possibilities are under investigation.
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